<DOC>
	<DOCNO>NCT00595972</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability ECF regimen ( epirubicin , cisplatin FU ) combine endostar -- inhibitor angiogenesis , patient advance metastatic gastric cancer ( A/MGC ) .</brief_summary>
	<brief_title>Epirubicin Cisplatin Fluorouracil ( FU ) Combined With Endostar Patients With Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description>Although standard regimen treatment metastatic gastric cancer , ECF regimen ( epirubicin , cisplatin FU ) often consider reference regimen . And ECF regimen suggest first line therapy A/MGC FDA . According result Chinese phase III clinical trial metastatic lung cancer , endostar -- new angiogenesis inhibitor prolong overall survival , time progression improve response rate . So designed clinical trial evaluate whether endostar bring survival benefit patient advance metastatic gastric cancer patient .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically confirm advanced metastatic adenocarcinoma stomach ECOG performance scale ≤ 2 At least one measurable lesion ( large 10 mm diameter spiral CT scan ) Adequate hepatic , renal , heart , hematologic function ( platelets＞80×109/L , neutrophil＞ 2.0 × 109/L , serum creatinine ≤ 1.5mg/dl , total bilirubin within upper limit normal ( ULN ) , serum transaminase ≤ 2.5×the ULN ) Pregnant lactate woman Concurrent cancer History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Neuropathy , brain , leptomeningeal involvement Clinically relevant coronary artery disease history myocardial infarction within last 12 month high risk/uncontrolled arrhythmia Uncontrolled significant comorbid condition previous radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Time Progression</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Response rate</keyword>
	<keyword>Quality Live</keyword>
	<keyword>Toxicities</keyword>
</DOC>